Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05345561 · ClinicalTrials.gov registry record
Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia
A clinical trial of Fetal and Neonatal Alloimmune Thrombocytopenia, sponsored by Rallybio.
- Completed
- Registry status
- 14,390
- Enrollment target
- 20
- Study locations
NCT05345561: Completed study of Fetal and Neonatal Alloimmune Thrombocytopenia, sponsored by Rallybio.
NCT05345561 is a study of Fetal and Neonatal Alloimmune Thrombocytopenia that has completed, run by Rallybio. The registered enrollment target is 14,390 participants. The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05345561, a study of Fetal and Neonatal Alloimmune Thrombocytopenia, has completed, sponsored by Rallybio.
- COMPLETED
- Registry status
- 14,390 participants
- Enrollment target
- 20
- Study locations
Study Summary
A prospective, non-interventional, natural history study to assess the occurrence of higher FNAIT risk across a broad population of different racial and ethnic characteristics and the occurrence of HPA-1a alloimmunization in these women.
Conditions Studied
Interventions
- OTHER Clinical data collection
Study Locations (20)
New Jersey
- Cooper University Hospital - Camden
- Robert Wood Johnson Medical School - New Brunswick
- St. Peter's University Hospital - New Brunswick
- Rutgers New Jersey Medical School - Newark
New York
- Icahn School of Medicine at Mount Sinai - New York
- Columbia University Irving Medical Center - New York
- New York-Presbyterian-Queens - New York
- Weill Cornell Medicine-New York Presbyterian Hospital - New York
Texas
- Javara Inc. - Forest - Dallas
- The University of Texas Health Science Center at Houston - Houston
- Javara Research Inc. - Dallas - PPDS - Houston
Ohio
- Ohio State University Wexner Medical Center - Columbus
- Wright State Physicians Obstetrics & Gynecology - Dayton
Arizona
- New Horizons Clinical Trials, LLC - Chandler
California
- Zillan Clinical Research - Gardena - Gardena
Connecticut
- Yale University School of Medicine - New Haven
Florida
- University of Miami Miller School of Medicine - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14,390 participants |
| Start Date | 2022-03-14 |
| Est. Completion | 2025-10-10 |
What the finished NCT05345561 record still lists
NCT05345561 is an observational study that tracks outcomes without assigning an intervention. Its 14,390 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Fetal and Neonatal Alloimmune Thrombocytopenia appearing as the primary indexed condition, and to 1 intervention - of which Clinical data collection is the first listed.
NCT05345561 names 20 study sites across 11 states, led by New Jersey, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT05345561 about?
NCT05345561 is a clinical study titled "Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia". A prospective, non-interventional, natural history study to assess the occurrence of higher FNAIT risk across a broad population of different racial and ethnic characteristics and the occurrence of HPA-1a alloimmunization in these women.
What is the current status of trial NCT05345561?
This trial is currently completed. The enrollment target is 14,390 participants. The study started on 2022-03-14. Estimated completion is 2025-10-10.
What conditions does trial NCT05345561 study?
This clinical trial studies the following conditions: Fetal and Neonatal Alloimmune Thrombocytopenia.
What interventions are being tested in trial NCT05345561?
The interventions under investigation include: Clinical data collection (OTHER).
Who is sponsoring clinical trial NCT05345561?
This trial is sponsored by Rallybio, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05345561 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05591066 · 14,400 participants · NA
The Patient and Family Centered I-PASS LISTEN Study: Language, Inclusion, Safety, and Teamwork for Equity Now
- NCT05359016 · 14,600 participants · NA
Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique
- NCT06849869 · 14,820 participants · NA
Collaborative Care Model for Perinatal Wellness Support Services - Population-Level Equity-Centered Systems Change
- NCT00857922 · 15,000 participants
Neurosciences Research Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI